Hangzhou Apextide Biomedical

Peptide and oligonucleotide CRDMO in Hangzhou Pharmaceutical Port, drawing on parent company Sinopep's 20 years of peptide experience. Milligram-to-ton custom synthesis including linear, cyclic, stapled, and highly modified peptides, plus API analysis and CMC submission support. 60kg annual peptide/oligonucleotide capacity. US DMF for tirzepatide filed 2024; FDA inspection 2024 closed VAI.

Directory assessment: Hangzhou Apextide Biomedical is listed as a CDMO in the peptide supply chain, serving Asia markets from China (Hangzhou). As a direct manufacturer, this supplier controls its own production process from synthesis through purification and quality control release testing. This profile lists 3 sources for reference. This supplier has a medium confidence score — verification signals are present, but the listing is newer or less documented; perform standard due diligence before engaging.